Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is associated with substantial ischemic risk, yet the optimal duration of dual antiplatelet therapy (DAPT) after successful CTO-PCI remains uncertain. We conducted a systematic review and meta-analysis comparing extended DAPT (>12 months) with short...
A. Emara, A. Mansour, Ahmed Wahdan Kasem et al.· Cardiology in Review· 0 citations
Abstract: Transcatheter aortic valve replacement (TAVR) is an established treatment for severe aortic stenosis, with self-expanding valves (SEV) and balloon-expandable valves (BEV) representing the two major platforms. However, their comparative clinical and hemodynamic performance remains uncertain. We systematically...
Ahmed Elazab, A. Ali, Ahmed Elbataa et al.· Cardiology in Review· 0 citations
Low-density lipoprotein cholesterol (LDL-C) is the principal target for preventing atherosclerotic cardiovascular disease, yet many patients do not reach treatment goals with statins, and established proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies require injections every 2-4 weeks. Recaticimab is a hu...
Ahmed Talkhan, Amr M. Abou Elezz, N. Borham et al.· Cardiology in Review· 0 citations
We used the National Inpatient Sample from 2016 to 2022 to compare complete revascularization with culprit-only percutaneous coronary intervention in adults hospitalized with non-ST-elevation myocardial infarction and multivessel disease. Hospitalizations complicated by cardiogenic shock, cardiac arrest, coronary arter...
M. Elkasaby, A. Alanazi, W. Frishman et al.· Cardiology in Review· 1 citation
Ongericimab is a humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9 that reduces LDL-C and increases apolipoprotein A1 and high-density lipoprotein cholesterol and increased apolipoprotein A1 and high-density lipoprotein cholesterol (all P < 0.0001).
Ahmed Talkhan, M. Elkasaby, Ahmed S. A. Osman et al.· Cardiology in Review· 0 citations
Selective aldosterone synthase inhibitors (ASIs), including baxdrostat and lorundrostat, target CYP11B2 while sparing cortisol synthesis, offering a novel strategy for resistant and uncontrolled hypertension. Yet existing meta-analyses have included nonselective agents or omitted the latest phase 3 data. We searched Pu...
N. Hammad, M. Elkasaby, A. Gadelmawla et al.· Cardiology in Review· 1 citation
Perioperative hyperglycemia in cardiac surgery is associated with wound infection, acute kidney injury, and death, yet the intravenous insulin used to treat it is itself coupled to hypoglycemia, yet the intravenous insulin used to treat it is itself coupled to hypoglycemia.
Ibrahim Gamal, M. Elkasaby, Osama Ewidat et al.· Cardiology in Review· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.